Peter Hirth - 26 May 2022 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Reporting relationship: Director
Issuer ticker: IOBT
Reported as of: 26 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 May 2022, 19:42:07 UTC
Prior SEC filing: 04 Nov 2021
Next SEC filing: 03 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian Burkavage, Attorney-in-Fact for Peter Hirth

Key filing fact

Peter Hirth filed Form 4 for IO Biotech, Inc. (IOBT) on 31 May 2022.

Key facts

This page summarizes Peter Hirth's Form 4 filing for IO Biotech, Inc. (IOBT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 May 2022, 19:42.

Change

Previous filing in this sequence was filed on 04 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOBT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,885
Change %
Price: $0.000000
Shares after: 23,885
Date: 26 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,885
Exercise price: $4.85
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.